Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: A systematic review of clinical studies.


Journal

Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 17 09 2018
accepted: 19 11 2018
pubmed: 21 12 2018
medline: 21 3 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

Many critically ill patients are exposed to opioids and benzodiazepines at high doses for prolonged periods, and upon discontinuation of these drugs, they may be at risk for iatrogenic withdrawal. Although this syndrome was associated with worse outcomes in the critically ill, limited guidance exists regarding its evaluation, prevention and treatment. This systematic review examined the frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and/or benzodiazepines in critically ill neonates, children and adults. The literature search was conducted in PubMed, Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane register of systematic reviews, DARE, CINAHL, Trip database, CMA infobase and NICE evidence from inception to February 2018. Grey literature was examined. We included studies reporting frequency, risk factors or symptomatology of iatrogenic withdrawal of opioids, benzodiazepines (or both) in critically ill patients. We considered all study designs except case reports and case series. We excluded studies on neonatal abstinence syndrome, alcohol withdrawal, studies on chronic opioid and/or benzodiazepine users and studies on prevention or treatment of withdrawal in critical care patients. Two independent reviewers applied the inclusion and exclusion criteria. Pairs of reviewers independently abstracted data and evaluated methodological quality using the Cochrane Collaboration Tool, Newcastle-Ottawa or QUADAS-2. Details regarding study design, outcomes, definition, evaluation and type of withdrawal (opioid, benzodiazepine or mixed) were collected. Cumulative doses and duration of opioids and benzodiazepines were collected. We identified 21 866 unique citations and 153 full texts were assessed for eligibility. Thirty-four studies were included; the majority were observational and few included adults. In prospective studies, mixed withdrawal was observed in 7.5%-100% of patients in paediatric studies and ranged from 16.7% to 55% in adults. Symptomatology of withdrawal was not well described. Risk factors included higher cumulative dose and prolonged administration of opioids and benzodiazepines. Iatrogenic withdrawal appears to be a frequent syndrome in critical care patients who received regular doses of opioids and/or benzodiazepines for ≥72 hours. Larger studies are required, especially in critically ill adults, to better define the syndrome and its symptomatology.

Identifiants

pubmed: 30569508
doi: 10.1111/jcpt.12787
doi:

Substances chimiques

Analgesics, Opioid 0
Benzodiazepines 12794-10-4

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-156

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Marc-Alexandre Duceppe (MA)

Pharmacy Department, McGill University Health Centre, Montreal, Quebec, Canada.

Marc M Perreault (MM)

Pharmacy Department, McGill University Health Centre, Montreal, Quebec, Canada.
Faculté de Pharmacie, Université de Montréal, Montreal, Quebec, Canada.

Anne Julie Frenette (AJ)

Faculté de Pharmacie, Université de Montréal, Montreal, Quebec, Canada.
Pharmacy Department, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.

Lisa D Burry (LD)

Pharmacy Department, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Philippe Rico (P)

Faculté de Médicine, Université de Montréal, Montreal, Quebec, Canada.
Department of Critical Care, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.

Annie Lavoie (A)

Faculté de Pharmacie, Université de Montréal, Montreal, Quebec, Canada.
Pharmacy Department, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.

Céline Gélinas (C)

Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
Centre for Nursing Research/Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.

Sangeeta Mehta (S)

Department of Medicine, Sinai Health System, and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.

Maryse Dagenais (M)

Pediatric Intensive Care Unit, McGill University Health Centre, Montreal, Quebec, Canada.

David R Williamson (DR)

Faculté de Pharmacie, Université de Montréal, Montreal, Quebec, Canada.
Pharmacy Department, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH